



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 20th OCTOBER 2021

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Ms Ana Batista	Specialist Pharmacist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Ms F Iqbal	Senior Pharmacist NHS BwD CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Dr T McKenzie (TM)	GP East Lancashire
Mr U Akram (UK)	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
Ms V Simpson	ELHT Homecare Pharmacist
Mr Z Hisham	Antimicrobial Stewardship Lead ELHT

2021/115: APOLOGIES:

Dr S Ramtoola (SR)	Consultant Physician, ELHT
Ms S Holgate	Pharmacist ELHT

2021/116: DECLARATION OF INTEREST [relevant to agenda items]

SJ declared an interest in item 2021/120 item c – PCNs are being incentivised to switch patients to more environmentally friendly inhalers.

2021/117: MINUTES OF SEPTEMBER Teams MEETING:

Accepted as a correct record

2021/101: MATTERS ARISING:

The following Items were closed:

- 2019/131 – actioned, JV to follow up progress
- 2021/094 – actioned, comments sent & VG to take to next group meeting
- 2021/101a – actioned
- 2021/109 – actioned – AB spoken to Marion Lieth who has agreed to update policy.



2021/119 NEW PRODUCT REQUEST – KLISYRI

Requested for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. The product has only recently received a product license and supporting literature reports that the recurrence rate is 73% at 12 months. The product can only be used once and is not appropriate for initiation in Primary Care. The following comments were also made:

It was considered that there are other suitable treatments available that were less costly to use. Further supporting information required to support request e.g pathway or first- and second-line treatment guideline. Dr Raza to be invited to next meeting.

Resolved: Klisyri not approved for inclusion on formulary, further information required.

2021/120: LSCMMG CONSULTATIONS (for November LSCMMG)

- a) Clonidine VMS New medicines Assessment - supportive of recommendation as Green restricted, but concern expressed that gabapentin is not recommended in NICE guidance for use in menopausal symptoms.
- b) Asthma guidelines (current version)
- c) Asthma guidelines (consultation) – the guideline is more reflective of GINA guidance and would benefit from the use of named products. inclusion of device pathway has no consistency. Also doses should not be written as OD but instead as once daily. Other comments included:
 - Concerns raised regarding the number of different inhalers coming through
 - Concerns raised that the focus is on steroid dose increase instead of trying other options (e.g. montelukast or LAMAs), it needs to be a clear pathway to reduce steroids doses which is not currently the case on the guideline
 - There needs to be clear information on the guideline regarding which ones are MDIs and DPIs (information not consistent throughout document) and there should information about the carbon footprint against each one to help guide the choice.
 - There should be a mention that all patients should have a MDI and spacer to deal with acute attacks as they won't be able to DPIs
 - Concerns raised regarding montelukast review at 2 weeks, it is to soon and NICE advised 4 to 8 weeks,



- d) OAB draft guideline – suggested that ACB score reference is included. Also noted that there appears to be some information/full pages that have been omitted.

Comments to be sent to LSCMMG

2021/121: LSCMMG RECOMMENDATIONS (from September LSCMMG)

Vitamin D position statement. Updated – NICE COVID rapid review guideline added – supportive of document but suggested that guideline mentions that supplies of Vitamin D made in the past directly to care homes are not to be continued by GPs. The title 'Prescribing of Vitamin D for the treatment, maintenance following treatment, prophylaxis of deficiency and insufficiency states and prevention of COVID-19' should be amended as this is not used for the prevention of COVID-19

Resolved: Position statement accepted for use, to adopt locally with above comments.

Comments to be fed back to LSCMMG

2021/122: STRATEGIC COMMISSIONING COMMITTEE DECISIONS (SCC) (previously known as the Joint Committee of CCGs [JCCCG] commissioning)

The following decisions have been approved by the Strategic Commissioning Committee and are for information. The decisions will apply in ELHE.

- a) Sodium Oxybate – Narcolepsy with cataplexy – **RED, Blueteq form required**
- b) Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) (Sativex®) - For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication - **AMBER 0 – CCG commissioned**

2021/123: FORMULARY UPDATES

Extra item: Fidaxomicin – Clostridioides difficile guidance (NG199) has been updated. Fidaxomicin replaces metronidazole as 2nd line choice for a first episode of mild, moderate or severe C.diff infection and is also the recommended antibiotic for a further episode of C.difficile infection within 12 weeks of symptom resolution (relapse). Supply issues in primary care may be an issue as Fidaxomicin is expensive and not regularly held as stock in community pharmacies. It was decided that supply options need to be explored further through microbiology and trust.

ACTION: MicroGuide® and formulary will be updated, and supply options looked into.



Resolved: Formulary will be amended accordingly.

2021/124: Topical Morphine SOP – updated – acknowledged by ELMMB

2021/125: Other items

- a) Forxiga® (dapaglifloxin) 10mg for the treatment of chronic kidney disease (CKD) - requested by Dr Ramtoola. NICE TA expected January 2022.

Resolved: await NICE guidance and assign as Grey traffic light

- b) Testosterone Shared Care Guideline – trust has requested if point 6 of the shared care guideline *‘Prescribe and monitor the patient for a minimum period of three months and until the patient is on a stable dose’* could be amended to reflect that primary care prescribe/supply the medication from month one, until the patient is reviewed, and dosage checked at 3 months by secondary care.

Comments to be sent to LSCMMG

- c) Free of Charge medicines schemes – VS presented the SPS guidance for for local adoption by ELMMB. The policy is NHSE/I approved and ratified by RMOC and provides clear guidance for the use of the Free of Charge medicines schemes. Requests would be documented and submitted to ELMMB for approval and would only be implemented where there is no NICE TA available/ or awaiting approval. Any benefits of using the scheme will be calculated and feedback sent to ELMMB.

Resolved: SPS Free of charge (FOC) medicines schemes policy approved by ELMMB

2021/126: NICE recommendations (from September)

	TA number	Recommendation	Traffic light
Bimekizumab for treating moderate to severe plaque psoriasis	TA723	Recommended	RED CCG Blueteq form
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer	TA724	Not Recommended	BLACK
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	TA725	Recommended	RED NHSE Commissioned
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA726	Unable to make a recommendation	BLACK



Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA727	Unable to make a recommendation	BLACK
Midostaurin for treating advanced systemic mastocytosis	TA728	Recommended	RED NHSE Commissioned
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria	TA729	Recommended	RED NHSE Commissioned
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)	TA730	Unable to make a recommendation	BLACK
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)	TA731	Unable to make a recommendation	BLACK

2021/127: EAMS (early access to medicines scheme)

- a) Abrocitinib in the treatment of severe atopic dermatitis
- b) Cipaglucosidase alfa with miglustat in the treatment of late-onset Pompe disease
- c) Nivolumab in combination with chemotherapy in the treatment of oesophagus and stomach cancer
- d) Avalglucosidase alfa in the treatment of Pompe disease

RESOLVED: the above were acknowledged by ELMMB

STANDING ITEMS

2021/128: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES –September 2021
Minutes acknowledged

AOB:

LR reported that monitoring of antibiotic prescribing in primary care shows we are doing well but since school open prescribing has shown an increased in children; a lot of children (<5yrs) reflects the viral infections. Chris Gardner emailed by LR to arrange educational sessions in primary care to see how to address increase of antibiotic prescribing with the peak starting in summer whereas it is usually in winter and may get out of the scale.

TM: reported said is tricky as bugs from winter are coming back in summer, we just got a winter surge in the summer.

SJ: Commented that possibly the problem is that that there is no face to face consultation with no chest listen to.



Session to be arranged with Dr Gardner to get feedback from primary care perspective.

NG136- Hypertension in Adults: diagnosis and management – acknowledged by ELMMB

DATE OF NEXT MEETING – Wednesday 17th November 2021 **12.45pm** via 'Microsoft Teams'



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 20th OCTOBER 2021

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/086	New Product Request (unlicensed) – Short Chain Fatty Acids – the directorate to provide updated information on dosing, length of treatment, costs & expected patient numbers per year	SH /VG	Nov 21
2021/101b	ELMMB Membership Divisional directors to be asked to review their members and suggest a nominated person to attend future meetings.	LR/VG	Nov 21
2021/123	Fidaxomicin – supply options to be explored	VG	Nov 21